Matthew M. Burke
Bristol-Myers Squibb (United States) · 16 works · 4,602 citations · h-index 10
Top works
- Nivolumab plus Ipilimumab in Advanced Melanoma
- Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma (MEL).
- Survival, Response Duration, and Activity By Braf Mutation (Mt) Status in a Phase 1 Trial of Nivolumab (Anti-Pd-1, Bms-936558, Ono-4538) and Ipilimumab (Ipi) Concurrent Therapy in Advanced Melanoma (Mel)
- Case Report: Response to Ipilimumab in a Patient With HIV With Metastatic Melanoma
- The experiences of unpartnered men with prostate cancer: a qualitative analysis
- Safety and activity of pembrolizumab in melanoma patients with untreated brain metastases.
- Safety and clinical activity of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in combination with ipilimumab in patients (pts) with advanced melanoma (MEL).
- Pregabalin for the Treatment of Painful Hand-Foot Skin Reaction Associated With Dabrafenib
- Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
- Melanoma and immunotherapy bridge 2015
- Correction to: Real-World Recurrence Rates and Economic Burden in Patients with Resected Early-Stage Melanoma
- Understanding and Managing Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Advanced Melanoma
- LB956 Adherence to adjuvant therapy in patients (pts) with resected melanoma
- Understanding the Skills Necessary for Advanced Practice Nurses in Oncology to Deliver Bad News to Patients with Cancer
- Bevacizumab for advanced breast cancer: Hope, hype, and hundreds of headlines.
- Real-world treatment patterns and clinical outcomes of advanced melanoma patients following disease progression on anti-PD-1-based therapy.